These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22736099)

  • 1. Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab.
    Hogan VE; Holweg CT; Choy DF; Kummerfeld SK; Hackney JA; Teng YK; Townsend MJ; van Laar JM
    Ann Rheum Dis; 2012 Nov; 71(11):1888-94. PubMed ID: 22736099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.
    Julià A; Barceló M; Erra A; Palacio C; Marsal S
    Pharmacogenomics; 2009 Oct; 10(10):1697-708. PubMed ID: 19842941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
    Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
    Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.
    Thurlings RM; Boumans M; Tekstra J; van Roon JA; Vos K; van Westing DM; van Baarsen LG; Bos C; Kirou KA; Gerlag DM; Crow MK; Bijlsma JW; Verweij CL; Tak PP
    Arthritis Rheum; 2010 Dec; 62(12):3607-14. PubMed ID: 20722020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
    Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
    Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.
    Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
    J Rheumatol; 2012 Feb; 39(2):240-6. PubMed ID: 22174201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium.
    Gutierrez-Roelens I; Galant C; Theate I; Lories RJ; Durez P; Nzeusseu-Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
    Arthritis Rheum; 2011 May; 63(5):1246-54. PubMed ID: 21337318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
    Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP
    Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
    Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
    Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.
    Sellam J; Rouanet S; Hendel-Chavez H; Abbed K; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Taoufik Y
    Arthritis Rheum; 2011 Dec; 63(12):3692-701. PubMed ID: 22127692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis.
    Vosslamber S; Raterman HG; van der Pouw Kraan TC; Schreurs MW; von Blomberg BM; Nurmohamed MT; Lems WF; Dijkmans BA; Voskuyl AE; Verweij CL
    Ann Rheum Dis; 2011 Jun; 70(6):1153-9. PubMed ID: 21444302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial.
    Sellam J; Marion-Thore S; Dumont F; Jacques S; Garchon HJ; Rouanet S; Taoufik Y; Hendel-Chavez H; Sibilia J; Tebib J; Le Loët X; Combe B; Dougados M; Mariette X; Chiocchia G
    Arthritis Rheumatol; 2014 Aug; 66(8):2015-25. PubMed ID: 24756903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis.
    Haringman JJ; Gerlag DM; Zwinderman AH; Smeets TJ; Kraan MC; Baeten D; McInnes IB; Bresnihan B; Tak PP
    Ann Rheum Dis; 2005 Jun; 64(6):834-8. PubMed ID: 15576415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.
    Kavanaugh A; Rosengren S; Lee SJ; Hammaker D; Firestein GS; Kalunian K; Wei N; Boyle DL
    Ann Rheum Dis; 2008 Mar; 67(3):402-8. PubMed ID: 17644541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.
    Sellam J; Hendel-Chavez H; Rouanet S; Abbed K; Combe B; Le Loët X; Tebib J; Sibilia J; Taoufik Y; Dougados M; Mariette X
    Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.